Long non-coding RNA SNHG22 facilitates hepatocellular carcinoma tumorigenesis and angiogenesis via DNA methylation of microRNA miR-16-5p

Yinxin Zhang, Changliang Lu, and Haiwei Cui

*Department of General Surgery, The Affiliated Jianhu Hospital of Nantong University, Jianhu People’s Hospital, Jianhu, Jiangsu Province, China; †Department of Operating Room, The Affiliated Jianhu Hospital of Nantong University, Jianhu People’s Hospital, Jianhu, Jiangsu Province, China

ABSTRACT
Hepatocellular carcinoma (HCC) is considered as a common malignancy worldwide. Considerable evidence has illustrated that abnormally expressed long noncoding RNAs (lncRNAs) are in a close correlation with the initiation and progression of various tumors, including HCC. LncRNA small nucleolar RNA host gene 22 (SNHG22) has been reported to play important roles in tumor initiation, but its role and mechanism are little known in HCC. In our report, we discovered the high level of SNHG22 in HCC tissues and cells, and the high expression of SNHG22 was correlated with unfavorable clinical outcome in HCC patients. Functional assays implied that SNHG22 deficiency suppressed cell proliferation, migration, invasion, and angiogenesis in vitro. Mechanistic exploration revealed that SNHG22 recruited DNMT1 to miR-16-5p DNA promoter through EZH2 and inhibited miR-16-5p transcription via DNA methylation. Finally, we verified that the suppression of miR-16-5p countervalued the suppressive effect of SNHG22 deficiency on HCC cell proliferation, migration, invasion, and angiogenesis. Conclusively, this study clarified the SNHG22/EZH2/DNMT1/miR-16-5p axis and revealed that SNHG22 could be an underlying biomarker for HCC.

KEYWORDS
SNHG22; miR-16-5p; dnmt1; ezh2; hepatocellular carcinoma

Introduction
Hepatocellular carcinoma (HCC) is known as the sixth common primary malignancy and is regarded as the third major reason of tumor-correlated death all over the world [1]. Extensive studies showed that the occurrence of HCC is involved in many risk factors; among which, cirrhosis and viral hepatitis B are identified as the common events in tumor incidence [2,3]. In the past few decades, massive financial resources were put into the research of therapeutic methods for HCC, which led to continuous progress in HCC treatment [4]. However, it remains relatively poor in the clinical outcome of HCC patients [5]. One reason is that a lot of patients are usually definitely diagnosed at the later stage that correlated with metastasis [6]. Thus, it is important to explore molecular mechanisms for the finding of more effective biomarkers underlying HCC progression.

With the continuous improvement in sequencing techniques, many new kinds of genes were recognized as key factors in physiological and pathological development [7]. Long noncoding RNAs (lncRNAs) are a cluster of transcripts exceeding 200 nucleotides and lacking the ability of protein-coding [8]. In recent years, extensive evidence has revealed that lncRNAs with aberrant expression are dysregulated in cancer progression. For example, lncRNA MAFG-AS1 promotes tumor progression in bladder urothelial carcinoma by regulating HuR/PTBP1 axis [9]. LINC00460 is highly expressed in colon cancer and upregulates ANXA2 to facilitate cell invasion, proliferation, epithelial–mesenchymal transition (EMT), and tumor growth through binding to miR-433-3p [10]. LncRNA GATA6-AS1 is downregulated and restrains lymph node metastasis (LNM) and EMT in gastric cancer via downregulating FZD4 expression to inactivate Wnt/β-catenin Signaling [11]. Previous study has also validated...
some HCC-related lncRNAs, such as LINC01224 [12], HOXA11-AS [13], and ID2-AS1 [14]. Therefore, it is valuable to inspect more HCC-relevant lncRNAs and investigate novel regulatory mechanisms for HCC therapy.

Small nucleolar RNA host gene 22 (SNHG22) is discovered as an oncogenic lncRNA and plays a vital role in some tumors. As reported, SNHG22 is found to enhance malignant phenotypes via the miR-324-3p/SUDS3 axis in triple-negative breast cancer [15]. Additionally, SNHG22 is upregulated and functions as an oncogene in epithelial ovarian carcinoma [16]. Nevertheless, it has not been elaborated the detailed role and mechanism of SNHG22 in HCC. The main objective of our research was to investigate its biological role and probable mechanism in HCC.

Aberrant DNA methylation and histone methylation have been identified in various human cancers [17]. EZH2 is a histone methyltransferase that specifically modulates histone H3 lysine 27 trimethylation (H3K27me3) [18], while DNMT1 is a DNA methyltransferase that catalyzes the process of cytosine base methylation [19]. Increasing evidence indicated that lncRNAs could directly interact with EZH1 or DNMT1 and epigenetically silence miRNA expression in HCC. For example, lncRNA HOTAIR suppressed miR-122 expression in HCC via DNMTs-mediated DNA methylation [20]. PVT1 epigenetically inhibited miR-214 expression by binding with EZH2 to promote the progression of HCC [21]. Moreover, miR-16-5p has been reported to act as a tumor suppressor in various types of cancers [22,23] and can inhibit tumorigenesis and chemoresistance of HCC [24,25]. However, the regulatory mechanisms of miR-16a need to be further elucidated.

The present study aimed to investigate the role and molecular mechanism of SNHG22 in HCC and the results demonstrated that SNHG22 contributed to HCC tumorigenesis and angiogenesis via DNA methylation of miR-16-5p, suggesting SNHG22 might serve as an effective target for HCC treatment.

Materials and methods

**Clinical samples**

Sixty paired tumor and adjacent non-tumor specimens were collected from HCC patients at Jianhu People’s Hospital. The clinicopathological characteristics of HCC patients were presented in Table 1, and it was found that high SNHG22 or low miR-16-5p expression was associated with tumor size, lymph node metastasis, and clinical stage, while there was no significant association with sex or age in patients with HCC (Table 1). Before the surgery, all patients had not received chemo- or radio- therapy, and each of them has provided written informed consent. In liquid nitrogen, the tissues were sharply frozen and then preserved at −80°C after surgical resection. For this study, the permission from Ethics Committee of Jianhu People’s Hospital was obtained.

**Cell lines**

Chinese Academy of Sciences Cell Bank (Shanghai, China) provided THLE-3 cell line (human normal liver cell line) and HCC cell lines (Huh7, HCCLM6, MHCC97H and SNU-398). All cells were maintained in DMEM with 1% penicillin-streptomycin and 10% fetal bovine serum (FBS, Gibco, USA) and cultured at 37 °C in a humidified incubator containing 5% CO2. In addition, Huh7 and HCCLM6 cell lines were treated with different concentrations (0, 1, and 5 µM) of 5-Aza-dC (5-Aza-2-deoxycytidine (5-Aza-dC; cat. no. S3196; Selleck Chemicals) for 48 h at 37 °C.

**Cell transfection**

Short hairpin RNA (sh-RNA) targeting SNHG22 (sh-SNHG22; 5′-GGGAGAGTCTATCCAAGGAA-3′), DNMT1 (sh-DNMT1; 5′-GCUACGAGAUCGAGUUCATT-3′), DNMT3A (sh-DNMT3A; 5′-GTGCAGAAACATCGAGGACAT-3′) and DNMT3B (sh-DNMT3B; 5′-AAGTGGAAGATACATTGCCT-3′) and matched control shRNA (sh-NC; 5′-UUUCGCGAAGUGUCACGUTT-3′) were provided by GenePharma (Shanghai, China). MiR-16-5p inhibitor (5′-CGCAGAUAUUACAGUGUCGCUA-3′) and NC inhibitor (5′-UUGUACUACACAAAGUACUG-3′) were also obtained from GenePharma. The above-mentioned plasmids (50 nM) were transfected into Huh7 and HCCLM6 cells by Lipofectamine 3000 (Invitrogen, Carlsbad, CA,
USA). Then, the transfection efficiency of these plasmids was confirmed by RT-qPCR after the incubation of 48 h.

**RT-qPCR analysis**

TRIzol reagent (Invitrogen) was used for the extraction of total RNA. Utilizing reverse-transcription system kit (Takara, Otsu, Japan), the total RNA was reverse transcribed into cDNA, and qPCR analysis was carried out by the standard SYBR Green PCR kit (Takara). Through a miRNA First-Strand cDNA Kit (TIANGEN, Beijing, China), the reverse transcription of miRNA was performed, and qPCR analysis was conducted with miRcute Plus miRNA qPCR Kit (Tiangen). Relative quantification analysis was carried out by $2^{-\Delta\DeltaCT}$ method. GAPDH (for lncRNA analysis) or U6 (for miRNA expression analysis) was taken as the negative control. The primers were as follows: SNHG22 forward, 5’-AGGAGAGCTGCTTCTCACAGG-3’ and reverse, 5’-TCTCAGGCTGATGTGTCTCC-3’; miR-16-5p forward, 5’-GGAAGATGAGGAGTCGCTG-3’ and reverse, 5’-GACTTGACTGGAAGGG TGGG-3’; GAPDH forward, 5’-CCCTGGACACC AGCACAAT-3’ and reverse, 5’-GGGCCGGAC TCGTCATCG-3’, U6 forward, 5’-GATTTCTTCCT CTCATCGCTCACAG-3’ and reverse, 5’-CTGCTTCATGATCGTTGCTTG-3’.

**Western blot**

Total protein was isolated using RIPA buffer (Beyotime), exposed to 10% SDS-PAGE, and transferred onto PVDF membranes (Millipore). Then, the membranes were incubated with anti-VEGF (ab150375; Abcam), anti-endoglin (ab252345; Abcam), and anti-GAPDH (ab8245; Abcam) overnight at 4 °C. Following the incubation of secondary antibody for 1 h. The protein signals were analyzed by the ECL system kit (Pierce, Rockford, USA) [26].

**CCK-8 assay**

The transfected HCC cells were seeded into 96-well plates (4 × 10^3 cells/well) and incubated for 0, 24, 48, and 72 h. Later, 10 μl of CCK8 reagent (Dojindo Laboratories) were added to incubate for another 2 h. At last, a microplate reader was used to measure the viability of cells [27].

**Transwell assay**

Transwell assay was used for assessing the migratory and invasive abilities of transfected HCC cells [28]. The transwell chambers (pore size, 8 μm) were precoated with Matrigel (BD Biosciences, NJ, USA) for invasion assay and were not precoated with Matrigel for migration assay. In brief, culture medium with 10% FBS was seeded into bottom chambers, and cells (5 × 10^4) in 100 μl serum-free medium were placed into top chambers. After incubation at 37°C for 24 h, non-migrated or non-invaded cells were removed by a cotton swab. Cells migrated or invaded into the bottom chamber were in fixation and staining with paraformaldehyde (4%) and crystal violet (0.1%). Under an optical microscope, cell numbers were counted.

**Tube formation assay**

As previously described, the standard Matrigel assay was applied to assess angiogenesis activity in vitro through the quantification of tube formation [29]. In brief, the conditioned medium was the suspension from the transfected Huh7 and HCCLM6 cells for 48 h. Then, the conditioned
medium was cultured in 24-well plates with 6 × 10^4 human umbilical vein endothelial cells (HUVECs), and growth-factor-reduced Matrigel (50 μl, BD Biosciences) was coated in each well. After 24 h, Zeiss inverted microscope (Carl Zeiss) was used to acquire capillary-like structures.

**Xenograft study**

Male BALB/c nude mice aged 4-week-old were from Shi Laike Company (Shanghai, China), and fed in specific pathogen-free (SPF) conditions. For imitating tumor growth in vivo, mice were inoculated with Huh7 cells (1 × 10^6) with transfection of sh-SNHG22 or sh-NC by subcutaneous injection. Every 4 days, tumor volume was recorded, and mice were sacrificed after 4 weeks. Then, tumors were weighted. The Animal Ethics Committee of Jianhu People’s Hospital approved animal studies.

**Immunohistochemistry (IHC)**

Tumor tissues acquired from mice were processed by paraformaldehyde (4%) for fixation, and then the fixed tissues were dehydrated and embedded in paraffin. Later, sections (4-mm-thick) were acquired via intersecting the paraffin-embedded tissues. Next, the sections were deparaffinized and incubated at 4°C overnight with Ki67 antibody (Abcam, MA, USA). After incubation with secondary antibody, sections were stained by hematoxylin and photographed under a microscope.

**Microvessel density (MVD) detection**

MVD in the xenografts was detected IHC. Based on MVD, the microvascular density was determined as previously described [30]. Briefly, the neovascular structure was defined by yellow/brown colored cells or areas which could distinguish from grands or proximal microvessel. The unconnected branches of neovascularization were also identified as a neovascular structure. For counting, five views were chosen at random on each slide and average value was utilized to show MVD of each slide. The average value more than MVD threshold was defined as MVD positive, and the average value was considered as MVD negative.

**Methylation-specific PCR**

As the manufacturer’s protocol, Monarch genomic DNA-purification kit (NEB) was applied to isolate the genomic DNA from Huh7 and HCCLM6 cells [31]. Then, the conversion of DNA samples was performed by Methylation-Gold kit (Zymo Research). Later, Taq 2× master mix (NEB) was used perform methylation-specific PCR and routine PCR for analyzing the methylation of miR-16-5p. Finally, to ensure that proper PCR products were acquired, PCR products were sequenced.

**Subcellular fractionation assay**

By Life Technologies’ PARIS kits (Hongfu Biotech, China), the isolated RNAs of cytoplasmic and nuclear were performed [32]. Briefly, 5 × 10^6 Huh7 or HCCLM6 cells were collected, washed, and placed in a fractionation buffer (350 μl). Then, the samples were centrifuged after incubation for 15 min at 4°C. Later, cytoplasmic section was removed from the nuclear fraction. Then, the lysis of nuclear fraction was conducted in cell disruption buffer, and then RNA isolation was performed by 2× Lysis/Binding Solution. At last, RNAs from nuclear and cytoplasmic fractions were assessed by qPCR, U6 (for nuclear transcript) or GAPDH (for cytoplasmic transcript) was used as the negative control.

**Chromatin immunoprecipitation (ChIP) assay**

Millipore Maga ChIP kit (YuSheng Biotech) was used for ChIP assay [33]. Cells were collected and treated with formaldehyde to cross-link DNAs and proteins. Next, the formaldehyde was quenched by placing the cells into glycine buffer. Later, DNA fragments (200–400 bp) produced by sonication were precipitated by anti-DNMT1 antibody (ab188453; Abcam), and anti-IgG antibody (as negative control; ab181236; Abcam). At last, level of precipitated DNAs was validated by RT-qPCR analysis.
RNA immunoprecipitation (RIP) assay

Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) was used for RIP assay [33]. In the lysis buffer, cells were lysed, and then cell lysates were immunoprecipitated with anti-IgG (Abcam) or anti-EZH2 (ab283270; Abcam) antibody. After the extraction and purification, immunoprecipitated RNA was reverse transcribed to cDNA for RT-qPCR using SNHG22-specific primers.

Co-IP assay

For Co-IP assay, pre-cleared cell lysate was centrifuged for 15 minutes at 12,000 rpm. Then, cell lysates and primary antibodies were co-incubated at 4 °C overnight. Later, protein Agarose beads (100 μL, GE Healthcare, USA) were added and incubated for 2 h at room temperature with gentle rotation. Using RIPA buffer, the precipitates were washed and then boiled in a loading buffer. Finally, the precipitates were analyzed by western blot, and normal rabbit IgG was taken as the internal control.

Statistical analysis

Statistical analyses were conducted by using SPSS 20.0 (SPSS, Chicago, IL, USA), and data were exhibited as mean ± SD. For evaluating statistical significance in two or multiple groups, the Student’s t-test or one-way ANOVA was employed. The Kaplan-Meier method was used to calculate the overall survival curve. P < 0.05 was considered as statistical significance.

Results

SNHG22 was highly expressed and correlated with unfavorable prognosis

At first, we used RT-qPCR to identify SNHG22 expression in HCC tissues and adjacent non-tumor tissues. It indicated that SNHG22 was considerably upregulated in HCC tissues compared with non-cancerous specimens (Figure 1(a)). Then, SNHG22 expression in THLE-3 cells and HCC cell lines was measured by RT-qPCR. As a result, SNHG22 also showed a higher level in HCC cell lines (Figure 1(b)). Moreover, we applied Kaplan–Meier analysis and discovered that HCC patients with high SNHG22 level presented shorter survival time than those with low SNHG22 level (Figure 1(c)). Taken together, SNHG22 was up-regulated and predicted poor prognosis.

SNHG22 silencing inhibited cell proliferation, invasion, and angiogenesis in vitro

To further investigate the role of SNHG22, we designed SNHG22 shRNA (sh-SNHG22) to silence SNHG22 expression in Huh7 and HCCLM6 cell lines, and its transfection efficiency was confirmed by RT-qPCR (Figure 2(a)). Then, CCK-8 assay was carried out to assess the effect of SNHG22 on HCC cell proliferative ability. We discovered SNHG22 silencing remarkably prohibited the proliferation of Huh7 and HCCLM6 cells (Figure 2(b)). Moreover, we applied the transwell and Matrigel angiogenesis assays to assess the role of SNHG22 in cell invasion and angiogenesis. The results demonstrated that SNHG22 silencing significantly inhibited cell invasion and angiogenesis (Figure 2(c)).

Figure 1. Relative SNHG22 expression in HCC tissues and cells and its correlation with patients' survival. (a) RT-qPCR analysis of relative SNHG22 expression in HCC tissues and adjacent non-cancerous tissues. (b) relative SNHG22 expression in HCC cell lines and THLE-3 cell line was detected by RT-qPCR. (c) correlation between SNHG22 expression and HCC patients' survival. **p < 0.01.
Moreover, angiogenesis of HUVECs in sh-SNHG22 group was considerably inhibited compared with sh-NC group (Figure 2(e)). In addition, through examining the angiogenesis factors, it was found that the silencing of SNHG22 decreased the protein levels of VEGF and endoglin in HCC cell lines (Figure 2(f)). Collectively, HCC cell proliferation, invasion, and angiogenesis were restrained by SNHG22 deficiency in vitro.

**SNHG22 deficiency suppressed tumor growth and angiogenesis in vivo**

Subsequently, the biological function of SNHG22 in tumorigenesis in vivo was evaluated. Then, Huh7 cells with stable transfection of sh-SNHG22 or sh-NC were inoculated into nude mice via subcutaneous injection. As we observed, compared to the control group, tumors in sh-
SNHG22 group were smaller (Figure 3(a)). Moreover, SNHG22 deficiency significantly inhibited the volume of tumors (Figure 3(b)). In addition, the weight of tumors from SNHG22-knockdown group was lighter than those from sh-NC group (Figure 3(c)). According to immunohistochemical staining, we observed that the silencing of SNHG22 reduced Ki67 positivity compared to control group (Figure 3(d)). Furthermore, it was found that the tumor MVD was decreased after Huh7 cells transfected with sh-SNHG22 (Figure 3(e)), indicating that SNHG22 knockdown inhibited angiogenesis. To be concluded, SNHG22 deficiency inhibited HCC tumor growth and angiogenesis in vivo.

**SNHG22 decreased miR-16-5p expression through DNA promoter methylation**

In this section, we studied the regulatory mechanism of SNHG22 in HCC. Considerable evidence has proved that lncRNAs often play a biological role in tumors via regulating or binding to microRNAs [34,35]. Previously, miR-16-5p has been reported in HCC. In our study, we further confirmed that miR-16-5p expression was down-regulated in HCC tissues and cells (Figure 4(a)). After the transfection of sh-SNHG22, we discovered that miR-16-5p expression was augmented (Figure 4(b)). Usually, lncRNAs modulate miRNAs via acting as ‘miRNA sponges’. However, through analyzing the sequences between SNHG22 and miR-16-5p, we did not find their potential-binding sites. This indicated that SNHG22 might regulate miR-16-5p expression via other approaches. DNA methylation was a vital pattern to modulate gene expression [36]; thus, we conjectured that miR-16-5p expression suppressed by SNHG22 might be attributed to DNA promoter methylation. Furthermore, methylation-specific PCR was applied to testify the function of SNHG22 on miR-16-5p promoter methylation. The results implied that SNHG22 deficiency attenuated methylation of miR-16-5p (Figure 4(c)). To further verify the function of DNA methylation in regulating miR-16-5p expression, 5-aza-dC (DNA methylation inhibitor) was used. It indicated that 5-aza-dC treatment

![Figure 3](image_url)

**Figure 3.** SNHG22 deficiency inhibited tumor growth and angiogenesis. (a) the tumors excised from the nude mice in sh-SNHG22 group or sh-NC group. (b) The volume of tumors in two groups was assessed. (c) the tumor weight from sh-SNHG22 group or sh-NC group. (d) IHC was used for detecting Ki67 expression in each group. (e) MVD was assessed in each group. *p < 0.05, **p < 0.01.
remarkably augmented miR-16-5p expression (Figure 4(d)). All data suggested that SNHG22 inhibited miR-16-5p expression by enhancing DNA promoter methylation.

**SNHG22 recruited DNMT1 to promote miR-16-5p DNA promoter methylation via EZH2**

Subsequently, we inspected the molecular mechanism by which SNHG22 facilitated miR-16-5p DNA promoter methylation. At first, the localization of SNHG22 in Huh7 and HCCLM6 cells was determined by the subcellular fractionation assay. Results revealed that SNHG22 showed higher expression in the nucleus than the cytoplasm in HCC cell lines (Figure 5(a)), indicating that SNHG22 might exert function and regulate gene expression via directly binding to RNA-binding proteins at the transcriptional level. It has been reported that DNA methyltransferases (DNMTs), including DNMT3A, DNMT3B, and DNMT1, played a crucial role in DNA promoter methylation [37]. To verify whether the DNMT regulated miR-16-5p DNA promoter methylation, sh-RNAs for DNMT1, DNMT3A, and DNMT3B were designed. RT-qPCR analysis manifested that only the deficiency of DNMT1 augmented miR-16-5p expression in Huh7 and HCCLM6 cells (Figure 5(b)). Therefore, we considered that DNMT1 might execute the DNA promoter methylation of miR-16-5p. In addition, we conducted ChIP assay to validate whether SNHG22 was necessary for DNMT1 interacting with miR-16-5p promoter region. The result showed that SNHG22 knockdown weakened the binding ability of DNMT1 to miR-16-5p promoter region (Figure 5(c)). Previous report has confirmed that lncRNAs locating in the nucleus could interact with EZH2 (a catalytic subunit of PRC2), and then modulate downstream target genes [38]. Importantly, it was also reported that lncRNAs could recruit DNMT1 to promote DNA promoter methylation of miRNAs via EZH2 [39]. According to RIP assay, we found that SNHG22 directly interacted with EZH2 in HCC cells (Figure 5(d)). In addition, Co-IP assay indicated that EZH2 could bind to DNMT1, and the binding was hampered when SNHG22 was knocked down (Figure 5(e)). All
results validated that SNHG22 enhanced the methylation of miR-16-5p DNA promoter through recruiting DNMT1 via EZH2.

**SNHG22 promoted cell proliferation, invasion, and angiogenesis via miR-16-5p**

Finally, rescue assays were performed to verify whether SNHG22 modulated HCC cell growth and angiogenesis via miR-16-5p. Firstly, the transfection efficiency of miR-16-5p inhibitor was detected, and the result showed that miR-16-5p expression was decreased with miR-16-5p inhibitor transfection (Figure 6(a)). CCK-8 assay confirmed that miR-16-5p inhibition rescued the suppressed proliferative ability caused by SNHG22 knockdown (Figure 6(b)). Based on the transwell assay, it was discovered that the inhibited migration and invasion of sh-SNHG22-transfected HCC cells were restored by miR-16-5p inhibition (Figure 6(c-d)). Furthermore, the angiogenesis inhibited by SNHG22 silencing was also counteracted with miR-16-5p inhibitor transfection (Figure 6(e)). Collectively, SNHG22 executed its function in HCC cells via miR-16-5p.

**Discussion**

The majority of mammalian genomes have been identified to be transcribed into non-coding RNAs [40]. Recently, more and more attention has been focused on IncRNA due to its regulatory role in gene expression [7]. It was reported that IncRNAs are involved in the immune microenvironment [41], cellular metabolism [42], metastasis [43], proliferation [44], invasion [45], chemotherapy resistance [46], and other characteristics of tumor cells. In HCC, some IncRNAs have been inspected and confirmed effectively in tumorigenesis [12,13,47]. LncRNA SNHG22 has been previously reported as a tumor facilitator in triple-negative breast cancer [15], epithelial ovarian carcinoma [16], and papillary thyroid cancer [48]. In this research, we validated that SNHG22 was upregulated in HCC, and its upregulation was correlated with dissatisfactory prognosis. Moreover, SNHG22 silencing suppressed cell proliferation, migration, invasion, and angiogenesis in vitro. In addition, the tumor growth and angiogenesis in vivo were also restrained by SNHG22 knockdown. This indicated that SNHG22 might function as an oncogene in HCC.
As a pattern of epigenetic regulation, DNA methylation is important in tumor occurrence and development [36,49]. It has been proved that lncRNA could modulate miRNA via DNA methylation [20]. MiR-16-5p has been previously validated to exert inhibitory function in colorectal cancer [50], neuroblastoma [51], and HCC [52]. In our study, miR-16-5p was lowly expressed in HCC, and its expression or DNA promoter methylation was inhibited after SNHG22 knockdown. Additionally, the treatment of 5-aza-dC lifted miR-16-5p expression. These results proved that SNHG22 could regulate miR-16-5p expression via DNA methylation.

It was well-known that the catalysis of DNA methylation process could be attributed to DNMTs, such as DNMT1, DNMT3A, and DNMT3B [37]. Different DNMT exerts an effect

---

**Figure 6.** SNHG22 promoted cell proliferation, migration, invasion and angiogenesis via miR-16-5p. (a) RT-qPCR analysis was performed to test the transfection efficiency of miR-16-5p inhibitor. (b) The proliferation of each group was assessed by CCK-8 assay. (c and d) The migration and invasion of the transfected cells were evaluated by transwell assay. (e) Tube formation assay was conducted to verify angiogenesis in each group. *p < 0.05, **p < 0.001.

| Group | NC inhibitor | miR-16-5p inhibitor |
|-------|--------------|---------------------|
| Huh7  | ![Graph](image1) | ![Graph](image2) |
| HCCLM6| ![Graph](image3) | ![Graph](image4) |

| Group | sh-NC | sh-SNHG22 | sh-SNHG22+miR-16-5p inhibitor |
|-------|-------|------------|-------------------------------|
| Huh7  | ![Graph](image5) | ![Graph](image6) | ![Graph](image7) |
| HCCLM6| ![Graph](image8) | ![Graph](image9) | ![Graph](image10) |

| Group | sh-NC | sh-SNHG22 | sh-SNHG22+miR-16-5p inhibitor |
|-------|-------|------------|-------------------------------|
| Huh7  | ![Graph](image11) | ![Graph](image12) | ![Graph](image13) |
| HCCLM6| ![Graph](image14) | ![Graph](image15) | ![Graph](image16) |

| Group | sh-NC | sh-SNHG22 | sh-SNHG22+miR-16-5p inhibitor |
|-------|-------|------------|-------------------------------|
| Huh7  | ![Graph](image17) | ![Graph](image18) | ![Graph](image19) |
| HCCLM6| ![Graph](image20) | ![Graph](image21) | ![Graph](image22) |
on methylation at different stages, and the DNMT also changes in diverse gene modulation [53]. In our research, we first confirmed SNHG22 was chiefly distributed in the nucleus. Then, we found that it was DNMT1 leading to the DNA promoter methylation of miR-16-5p by RT-qPCR. Importantly, SNHG22 increased the binding capacity between DNMT1 and miR-16-5p promoter. A former study supported that lncRNA POU3F3 could interact with EZH2 to recruit DNMTs [54]; thus, we performed RIP assay and confirmed the direct binding of EZH2 to SNHG22. More importantly, it was identified that SNHG22 could increase the binding of EZH2 to DNMT1. Collectively, SNHG22 could recruit DNMT1 to promote miR-16-5p DNA promoter methylation by EZH2.

**Conclusion**

Our study demonstrated that SNHG22 facilitated HCC progression by modulating miR-16-5p methylation. Our discovery revealed the underlying role and mechanism of SNHG22 and validated SNHG22/EZH2/DNMT1/miR-16-5p regulatory axis in HCC, which provided the valuable theoretical basis for HCC treatment. However, the present study has several limitations, which remain to be addressed. For example, other downstream effectors may also be important in SNHG22-regulated phenotypes of HCC, which needs to be further investigated.

**ORCID**

Haiwei Cui [http://orcid.org/0000-0002-1583-4900](http://orcid.org/0000-0002-1583-4900)

**References**

[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians. 2016;66(2):115–132.
[3] Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153–159.
[4] Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
[5] Kudo M, Kitano M, Sakurai T, et al. Challenges of Clinical Research on Hepatocellular Carcinoma. Dig Dis. 2015;33(6):780–790.
[6] Goh V, Sarker D, Osmany S, et al. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(6):1070–1079.
[7] Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–914.
[8] Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
[9] Xiao M, Liu J, Xiang L, et al. MAFG-AS1 promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma. Clin Transl Med. 2020;10:e241.
[10] Hong W, Ying H, Lin F, et al. lncRNA LINC00460 Silencing Represses EMT in Colon Cancer through Downregulation of ANXA2 via Upregulating miR-433-3p. Mol Ther Nucleic Acids. 2020;19:1209–1218.
[11] Li ZT, Zhang X, Wang DW, et al. Overexpressed IncRNA GATA6-AS1 Inhibits LNM and EMT via FZD4 through the Wnt/β-Catenin Signaling Pathway in GC. Mol Ther Nucleic Acids. 2020;19:827–840.
[12] Gong D, Feng PC, Ke XF, et al. Silencing Long Non-coding RNA LINC01224 Inhibits Hepatocellular Carcinoma Progression via MicroRNA-330-5p-Induced Inhibition of CHEK1. Mol Ther Nucleic Acids. 2020;19:482–497.
[13] Guo JC, Yang YJ, Zheng JF, et al. Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. Exp Mol Med. 2019;51(11):1–20.
[14] Zhou Y, Huan L, Wu Y, et al. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer Lett. 2020;469:399–409.
[15] Fang X, Zhang J. Long non-coding RNA SNHG22 facilitates the malignant phenotypes in triple-negative breast cancer via sponging miR-324-3p and upregulating SUDS3. Cancer Cell Int. 2020;20:252.
[16] Zhang PF, Wu J, Luo JH, et al. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467-Gal-1 signaling pathway in epithelial ovarian carcinoma. Aging (Albany NY). 2019;11(19):8204–8216.
[17] Zhang C, Li H, Wang Y, et al. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J Hepatol. 2010;53(5):889–895.
[18] Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298(5595):1039–1043.
[19] Ting AH, Jair KW, Schuebel KE, et al. Differential requirement for DNA methyltransferase 1 in
maintaining human cancer cell gene promoter hypermethylation. Cancer Res. 2006;66(2):729–735.

[20] Cheng D, Deng J, Zhang B, et al. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159–170.

[21] Gou X, Zhao X, Wang Z. Long noncoding RNA PVT1 promotes hepatocellular carcinoma progression through regulating miR-214. Cancer Biomarkers. 2017;20(4):511–519.

[22] Ruan L, Qian X. MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-kB pathway. Biosci Rep. (2019):39:

[23] Liang H, Fu Z, Jiang X, et al. miR-16 promotes the apoptosis of human cancer cells by targeting FEAT. BMC Cancer. 2015;15(1):448.

[24] Zhou Y, Huang Y, Dai T, et al. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Biomed Pharmacother. 2021;133:110130.

[25] Qi F, Zhou S, Li L, et al. Pien Tze Huang inhibits the growth of hepatocellular carcinoma cells by upregulating miR-16 expression. Oncol Lett. 2017;14:8132–8137.

[26] Cai L, Ye L, Hu X, et al. MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4. Bioengineered. 2021;12(1):440–449.

[27] Liu A, Zhang B, Zhao W, et al. Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-kB and MAPKs signaling pathways. Bioengineered. 2021;12(1):183–195.

[28] Liu Y, Zhang H, Wang H, et al. Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4. Bioengineered. 2021;12:496–506.

[29] Würdinger T, Tannous BA, Saydam O, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008;14 (5):382–393.

[30] Takagi K, Takada T, Amano H, et al. Analysis of microvessels in pancreatic cancer: by light microscopy, confocal laser scan microscopy, and electron microscopy. J Hepatobiliary Pancreat Surg. 2008;15 (4):384–390.

[31] Wang XX, Guo GC, Qian XX, et al. miR-506 attenuates methylation of lncRNA MEG3 to inhibit migration and invasion of breast cancer cell lines via targeting SP1 and SP3. Cancer Cell Int. 2018;18(1):171.

[32] Zhu Y, Hu H, Yuan Z, et al. LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness. Cell Death Dis. 2020;11:962.

[33] Li Z, Yu Z, Meng X, et al. LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2. Biochem Biophys Res Commun. 2018;504 (2):499–504.

[34] Müller V, Oliveira-Ferrer L, Steinbach B, et al. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. Mol Oncol. 2019;13:1137–1149.

[35] Huang Y, Xu Y, Lu Y, et al. LncRNA Gm10451 regulates PTIP to facilitate iPSCs-derived β-like cell differentiation by targeting miR-338-3p as a ceRNA. Biomaterials. 2019;216:119266.

[36] Greenberg MVC, Bour’chis D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20(10):590–607.

[37] Zong L, Abe M, Seto Y, et al. The challenge of screening for early gastric cancer in China. Lancet. 2016;388 (10060):2606.

[38] Xu Y, Yao Y, Jiang X, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res. 2018;37(1):81.

[39] Jin L, Cai Q, Wang S, et al. Long noncoding RNA PVT1 promoted gallbladder cancer proliferation by epigenetically suppressing miR-18b-5p via DNA methylation. Cell Death Dis. 2020;11:871.

[40] Djebari S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489 (7414):101–108.

[41] Wang QM, Lian GY, Song Y, et al. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019;231:116335.

[42] Deng SJ, Chen HY, Zeng Z, et al. Nutrient Stress-Dysregulated Antisense LncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Cancer Res. 2019;79:1398–1412.

[43] Kawasaki Y, Miyamoto M, Oda T, et al. The novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis. EMBO Rep. 2019;20:e47052.

[44] Wang CJ, Zhu CC, Xu J, et al. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer. 2019;18:115.

[45] Saeinastab M, Bahrami AR, González J, et al. SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF. J Exp Clin Cancer Res. 2019;38 (1):172.

[46] Chang ZW, Jia YX, Zhang WJ, et al. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESCI. J Exp Clin Cancer Res. 2018;37(1):56.

[47] Tian X, Wu Y, Yang Y, et al. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling. Mol Oncol. 2020;14:462–483.
[48] Gao H, Sun X, Wang H, et al. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer. Cell Cycle. 2020;19(10):1186–1199.

[49] Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459–466.

[50] Wu H, Wei M, Jiang X, et al. IncRNA PVT1 Promotes Tumorigenesis of Colorectal Cancer by Stabilizing miR-16-5p and Interacting with the VEGFA/VEGFR1/AKT Axis. Mol Ther Nucleic Acids. 2020;20:438–450.

[51] Chava S, Reynolds CP, Pathania AS, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020;14:180–196.

[52] Liu Z, Wang Y, Wang L, et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):194.

[53] Cedar H, Bergman Y. Programming of DNA methylation patterns. Annu Rev Biochem. 2012;81(1):97–117.

[54] Li W, Zheng J, Deng J, et al. Increased levels of the long intergenic non-protein coding RNA POU3F3 promote DNA methylation in esophageal squamous cell carcinoma cells. Gastroenterology. 2014;146(7):1714–1726. e1715.